Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Some of Wall Street’s biggest upside calls are not sitting in the mega-cap names.

They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.

That is what makes them interesting, as in each case, the investment thesis comes down to a binary trigger: a trial result, a commercial turn, or a regulatory step that could force the market to revalue the stock fast.

That is the setup behind Atai Life Sciences, Vivos Therapeutics and Actuate Therapeutics.

Atai Life Sciences: A high-conviction wager

Atai Life Sciences is the most closely followed name on this list, and arguably the easiest for investors to understand.

The clinical-stage biotech is focused on psychedelic-assisted therapies for mental health conditions, particularly treatment-resistant depression.

The stock recently traded near $4, but Wall Street sees much more upside.

Current analyst targets cluster around the mid-teens, implying potential gains of nearly 300%.

Canaccord Genuity recently raised its price target to $15 from $14 while maintaining a Buy rating, citing encouraging clinical progress.

Broader sentiment toward the sector also improved in April after the White House moved to accelerate regulatory reviews of psychedelic therapies, giving the group a fresh tailwind.

Vivos Therapeutics: The lowest-priced name

Vivos Therapeutics is the most speculative of the three.

The stock recently traded around 97 cents, and H.C. Wainwright cut its target to $2.50 from $7 while keeping a Buy rating.

That still implies a very large gain, but the more important detail is the caveat.

The firm said dilution “may be inevitable” as Vivos needs additional capital, though it remained “cautiously optimistic” that operations could improve and revenue could keep growing in 2026.

That is why Vivos is a trader’s stock, not a core holding.

The bull case is that obstructive sleep apnea is a huge market and the company is trying to position its oral appliance therapy as an alternative to CPAP.

The problem is execution and financing, as in small-cap medtech, those two risks usually decide the stock long before the market can reward the product story.

Actuate Therapeutics: A classic binary biotech setup

The third name, Actuate Therapeutics, fits the same pattern in a more traditional biotech way.

H.C. Wainwright recently lowered its target to $15 from $20 but kept a Buy rating.

The stock was trading around $1.72 at the time, which leaves substantial upside if the company keeps advancing its lead program.

In a mid-stage trial, 44% of advanced pancreatic-cancer patients receiving Actuate’s experimental drug with chemotherapy were alive after one year, compared with 22% on chemotherapy alone.

Median survival also improved to 10.1 months from 7.2 months.

That kind of data is exactly what can move a small biotech sharply higher.

It does not guarantee success, and it does not remove the need for Phase 3 confirmation.

But it does turn a stock from a pure concept into a company with a real, measurable signal.

H.C. Wainwright said Actuate is now weighing multiple commercialization paths for elraglusib and planning a confirmatory Phase 3 study, which is the sort of milestone investors watch closely in this sector.